6,517 results match your criteria anakinra


Hospital-Acquired Bloodstream Infections in Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 Infection (Coronavirus Disease 2019): Association With Immunosuppressive Therapies.

Open Forum Infect Dis 2021 Jul 30;8(7):ofab339. Epub 2021 Jun 30.

Division of Infectious Diseases, Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Health, Manhasset, New York, USA.

Background: Immunosuppressive therapies proposed for Coronavirus disease 2019 (COVID-19) management may predispose to secondary infections. We evaluated the association of immunosuppressive therapies with bloodstream-infections (BSIs) in hospitalized COVID-19 patients.

Methods: This was an institutional review board-approved retrospective, multicenter, cohort study of adults hospitalized with COVID-19 over a 5-month period. Read More

View Article and Full-Text PDF

Current treatment of recurrent pericarditis: safety considerations and future directions.

Authors:
Massimo Imazio

Expert Opin Drug Saf 2021 Aug 2. Epub 2021 Aug 2.

Cardiology, Cardiothoracic Department, Santa Maria della Misericordia University Hospital, Azienda Sanitaria Universitaria del Friuli Centrale (ASUFC), Udine, Italy.

Introduction: Recurrent pericarditis is one of the most troublesome complications of pericarditis affecting a substantial amount of patients and often severely impairing the quality of life. Current medical treatments range from non-steroidal anti-inflammatory drugs (NSAIDs), colchicine and corticosteroids to biological agents (anti IL-1 agents, especially anakinra and rilonacept), intravenous immunoglobulins and immunosuppressive treatments. Safety is a major issue to deal with since the disease often affects relatively young or middle-aged patients. Read More

View Article and Full-Text PDF

Cerebrospinal fluid cytokine, chemokine, and SARS-CoV-2 antibody profiles in children with neuropsychiatric symptoms associated with COVID-19.

Mult Scler Relat Disord 2021 Jul 24;55:103169. Epub 2021 Jul 24.

Children's Healthcare of Atlanta, Division of Pediatric Neurology, Atlanta GA, United States; Emory University School of Medicine, Department of Pediatrics, Division of Neurology. Electronic address:

Background: Neuropsychiatric symptoms and CSF cytokine, chemokine, and SARS-COV-2 antibody profiles are unknown in pediatric patients with COVID-19 or multisystem inflammatory syndrome (MIS-C), (NP-COVID-19).

Methods: Children at a single pediatric institution quaternary referral center with laboratory-confirmed COVID-19 or MIS-C and neuropsychiatric symptoms were included in this retrospective case series. Clinical symptoms, ancillary testing data, treatments and outcomes are described. Read More

View Article and Full-Text PDF

An update of targeted therapeutic options for primary Sjögren syndrome: current status and future development.

Expert Opin Pharmacother 2021 Jul 29:1-13. Epub 2021 Jul 29.

Laboratory of Autoimmune Diseases Josep Font, IDIBAPS-CELLEX, Barcelona, Spain.

: Primary Sjögren syndrome (pSS) is a systemic autoimmune disease that may affect 3 in 1,000 people within the general population. The therapeutic scenario is complex, and no therapy has proved to be able to modify the natural course of the disease, nor to prevent the most severe systemic complications.: Recently, the EULAR 2020 Recommendations for pSS have underlined the low level of evidence supporting efficacious therapeutic approaches, lacking a definition of specific treatment targets and being far from the 'disease modification' concept that is frequently used in other diseases. Read More

View Article and Full-Text PDF

Autoimmune and Autoinflammatory Pericarditis: Definitions and New Treatments.

Curr Cardiol Rep 2021 07 28;23(9):128. Epub 2021 Jul 28.

Department of Biomedical and Clinical Sciences, Fatebenefratelli Hospital, Università di Milano, Milan, Italy.

Purpose Of The Review: The purpose of the review is to analyze the pathogenetic mechanisms that underlie acute pericarditis, with attention to autoimmune and autoinflammatory pericarditis, and, in addition, to review the available therapeutic armamentarium.

Recent Findings: Several studies have been published on the use of anti-IL-1 drugs in recurrent pericarditis, including anakinra and rilonacept. The latest, the RHAPSODY study, based on the use of rilonacept in recurrent pericarditis, has recently reached phase 3 with promising results in terms of efficacy and safety. Read More

View Article and Full-Text PDF

Psoriasis as an adverse reaction to biologic agents beyond anti-TNF-α therapy.

Eur J Dermatol 2021 Jun;31(3):307-317

Joint Rheumatology Program, 1st Department of Propaedeutic Internal Medicine-Rheumatology Unit, National and Kapodistrian University of Athens, School of Medicine, Laikon General Hospital, Ag. Thoma 17, 11527, Athens, Greece.

New onset or exacerbation of pre-existing psoriasis after therapeutic TNF-α inhibition is a well-described phenomenon. Over the last two decades, similar cases of paradoxical psoriasis have been reported following the administration of other biologic agents. We aimed to review all published cases of induced or exacerbated psoriasis after biologic therapy other than anti-TNF-α agents in order to further elucidate the pathophysiology of this phenomenon. Read More

View Article and Full-Text PDF

Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome-Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA Network.

Front Med (Lausanne) 2021 8;8:668173. Epub 2021 Jul 8.

Department of Medical Sciences, Surgery and Neurosciences, Research Center of Systemic Autoinflammatory Diseases and Behçet's Disease and Rheumatology-Ophthalmology Collaborative Uveitis Center, University of Siena, Siena, Italy.

To describe the role of biotechnological therapies in patients with tumor necrosis factor receptor associated periodic syndrome (TRAPS) and to identify any predictor of complete response. Clinical, laboratory, and therapeutic data from 44 Caucasian TRAPS patients treated with biologic agents were retrospectively collected in 16 Italian tertiary Centers. A total of 55 biological courses with anakinra ( = 26), canakinumab ( = 16), anti-TNF-α agents ( = 10), and tocilizumab ( = 3) were analyzed. Read More

View Article and Full-Text PDF

The role of IL-1 in adipose browning and muscle wasting in CKD-associated cachexia.

Sci Rep 2021 Jul 23;11(1):15141. Epub 2021 Jul 23.

Division of Pediatric Nephrology, Rady Children's Hospital, University of California, San Diego, 9500 Gilman Drive, MC 0831, La Jolla, CA, 92093-0831, USA.

Cytokines such as IL-6, TNF-α and IL-1β trigger inflammatory cascades which may play a role in the pathogenesis of chronic kidney disease (CKD)-associated cachexia. CKD was induced by 5/6 nephrectomy in mice. We studied energy homeostasis in Il1β/CKD, Il6/CKD and Tnfα/CKD mice and compared with wild type (WT)/CKD controls. Read More

View Article and Full-Text PDF

IL-1B drives opposing responses in primary tumours and bone metastases; harnessing combination therapies to improve outcome in breast cancer.

NPJ Breast Cancer 2021 Jul 21;7(1):95. Epub 2021 Jul 21.

Department of Oncology and Metabolism, Weston Park Cancer Centre, University of Sheffield, Sheffield, UK.

Breast cancer bone metastasis is currently incurable, ~75% of patients with late-stage breast cancer develop disease recurrence in bone and available treatments are only palliative. We have previously shown that production of the pro-inflammatory cytokine interleukin-1B (IL-1B) by breast cancer cells drives bone metastasis in patients and in preclinical in vivo models. In the current study, we have investigated how IL-1B from tumour cells and the microenvironment interact to affect primary tumour growth and bone metastasis through regulation of the immune system, and whether targeting IL-1 driven changes to the immune response improves standard of care therapy for breast cancer bone metastasis. Read More

View Article and Full-Text PDF

IL-1β-induced Elevation of SLC7A11 Promotes Hepatocellular Carcinoma Metastasis through Upregulating PD-L1 and CSF1.

Hepatology 2021 Jul 20. Epub 2021 Jul 20.

Department of Gastroenterology, Institute of Liver and Gastrointestinal Diseases, Hubei Key Laboratory of Hepato-Pancreato-Biliary Diseases, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei Province, China.

Background & Aims: Due to paucity of effective treatment options, metastasis is still a major cause for hepatocellular carcinoma (HCC)-associated mortality. Molecular mechanism of inflammation-induced HCC metastasis is largely unknown. Here, we characterized the function of solute carrier family 7 member 11 (SLC7A11) in inflammation-related HCC metastasis and probed therapy strategies for this subpopulation patients. Read More

View Article and Full-Text PDF

Case Report: Rapid Recognition and Immune Modulation of Secondary HLH Due to Disseminated HSV Infection.

Front Pediatr 2021 2;9:681055. Epub 2021 Jul 2.

Penn State University College of Medicine, Hershey, PA, United States.

We describe the case of a newborn who presented with multiple organ dysfunction syndrome (MODS) and hyperferritinemia, who eventually met criteria for hemophagocytic lymphohistiocytosis (HLH) due to disseminated herpes simplex virus 1 (HSV-1). While the cytokine storm abated after administration of multiple immune modulatory therapies including dexamethasone, etoposide, intravenous immune globulin, anakinra, as well as the interferon gamma antagonist emapalumab, multiple organ dysfunction syndrome progressed. Care was withdrawn after 5 days. Read More

View Article and Full-Text PDF

Schnitzler's Syndrome: A Diagnostic Consideration in Evaluating the Constellation of Monoclonal Gammopathy and Chronic Urticaria.

J Hematol 2021 Jun 16;10(3):143-146. Epub 2021 Jun 16.

Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA.

Schnitzler's syndrome is a rare clinical entity characterized by intermittent, non-pruritic urticarial rash, fevers, arthralgias, myalgias and monoclonal gammopathy, most commonly of the immunoglobulin M (IgM) subtype. Schnitzler's syndrome should be considered in the differential diagnosis of fever of unknown origin. We report a case of a 56-year-old healthy Caucasian female, who initially presented to the primary care physician's office with complaints of severe generalized fatigue and myalgias involving thighs and calves. Read More

View Article and Full-Text PDF

Use of Anakinra in steroid dependent recurrent pericarditis: a case report and review of literature.

J Community Hosp Intern Med Perspect 2021 21;11(4):543-546. Epub 2021 Jun 21.

Internal Medicine Department, Creighton University School of Medicine, Omaha, NE, USA.

Non-steroidal anti-inflammatory drugs and colchicine are the cornerstone treatment for recurrent pericarditis. Corticosteroids are frequently used in patients with recurrent episodes of pericarditis. In patients with corticosteroid dependent and corticosteroid-resistant pericarditis, several steroid-sparing options like azathioprine, intravenous immunoglobulin (IVIG), and anakinra are being recently tried. Read More

View Article and Full-Text PDF

Long-term safety and efficacy of anakinra and canakinumab in patients with familial Mediterranean fever: a single-centre real-life study with 101 patients.

Clin Exp Rheumatol 2021 Jun 21. Epub 2021 Jun 21.

Division of Rheumatology, Department of Internal Medicine, Gazi University Faculty of Medicine, Ankara, Turkey.

Objectives: Anakinra and canakinumab are the most commonly used agents in colchicine resistant/intolerant patients. In this study we investigated long-term efficacy and safety of anakinra and canakinumab.

Methods: In this retrospective study, we enrolled 101 adult patients with familial Mediterranean fever (FMF). Read More

View Article and Full-Text PDF

Anakinra-induced psoriasis in a patient with Schnitzler's syndrome.

Clin Exp Rheumatol 2021 Jul 7. Epub 2021 Jul 7.

Department of Dermatology, Hospital Universitari de Bellvitge, University of Barcelona, Spain.

View Article and Full-Text PDF

Improving outcomes for patients hospitalised with gout: a systematic review.

Rheumatology (Oxford) 2021 Jul 10. Epub 2021 Jul 10.

Centre for Rheumatic Disease, King's College London, London, UK.

Objectives: Hospital admissions for gout flares have increased dramatically in recent years, despite widely available, effective medications for the treatment and prevention of flares. We conducted a systematic review to evaluate the effectiveness and implementation of interventions in patients hospitalised for gout flares.

Methods: A search was conducted in MEDLINE, Embase and the Cochrane library, from database inception to 8 April 2021, using the terms gout and hospital and their synonyms. Read More

View Article and Full-Text PDF

Novel Use of Extracorporeal Blood Purification for Treatment of Severe, Refractory Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy-A Case Report.

Crit Care Explor 2021 Jul 29;3(7):e0472. Epub 2021 Jun 29.

Department of Critical Care Medicine, Mayo Clinic, Phoenix, AZ.

Background: Chimeric antigen receptor T-cell therapies (CAR-T) are transforming the treatment of B-cell leukemias and lymphomas. Cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome represent common, potentially life-threatening toxicities from chimeric antigen receptor T-cell therapy treatment.

Case Summary: We present a 53-year-old patient with primary refractory high-grade B-cell lymphoma who developed severe, refractory neurotoxicity following chimeric antigen receptor T-cell therapy but exhibited complete recovery after extracorporeal blood purification with CytoSorb (CytoSorbents, Monmouth Junction, NJ). Read More

View Article and Full-Text PDF

Multisystem inflammatory syndrome in children: A single-center experience.

Pediatr Int 2021 Jul 6. Epub 2021 Jul 6.

Department of Pediatrics, Dicle University Medical Faculty, Diyarbakır, Turkey.

Background: This case series aims to evaluate the presenting symptoms, laboratory data, systemic findings, and response to early treatment in patients who were followed up with the diagnosis of multisystemic inflammatory syndrome associated with novel coronavirus disease 2019 (COVID-19).

Methods: The presentation, laboratory findings, and responses to treatment of patients hospitalized and diagnosed with multisystemic inflammatory syndrome were evaluated retrospectively.

Results: A total of 32 patients were included in the study. Read More

View Article and Full-Text PDF

Features and Outcomes of Microcrystalline Arthritis Treated by Biologics: A Retrospective Study.

Rheumatol Ther 2021 Jul 4. Epub 2021 Jul 4.

Rheumatology Department, CHU, Centre de Référence Maladies Rares CERAINO, INSERM 1227, UBO, LabEx IGO, Brest CHU, Brest, France.

Objectives: The usual treatments for crystal-associated arthritis are sometimes contraindicated; thus, new therapies against interleukin-1beta (IL-1) have been developed. We evaluated the characteristics of patients who received biological treatment for crystal-associated arthritis.

Patients And Methods: We conducted a multicentric retrospective observational study in six rheumatology units in western France. Read More

View Article and Full-Text PDF

The Safety and Efficacy of Anakinra, an Interleukin-1 Antagonist in Severe Cases of COVID-19: A Systematic Review and Meta-Analysis.

Infect Chemother 2021 Jun;53(2):221-237

Larkin Community Hospital, Miami, FL, USA.

This study aims to assess anakinra's safety and efficacy for treating severe coronavirus disease 2019 (COVID-19). Numerous electronic databases were searched and finally 15 studies with a total of 3,530 patients, 757 in the anakinra arm, 1,685 in the control arm were included. The pooled adjusted odds ratio (OR) for mortality in the treatment arm was 0. Read More

View Article and Full-Text PDF

Towards a Treatment for Neuroinflammation in Epilepsy: Interleukin-1 Receptor Antagonist, Anakinra, as a Potential Treatment in Intractable Epilepsy.

Int J Mol Sci 2021 Jun 11;22(12). Epub 2021 Jun 11.

Department of Pediatrics and Adolescent Medicine, Tokyo Medical University, Tokyo 160-0023, Japan.

Febrile Infection-Related Epilepsy Syndrome (FIRES) is a unique catastrophic epilepsy syndrome, and the development of drug-resistant epilepsy (DRE) is inevitable. Recently, anakinra, an interleukin-1 receptor antagonist (IL-1RA), has been increasingly used to treat DRE due to its potent anticonvulsant activity. We here summarized its effects in 38 patients (32 patients with FIRES and six with DRE). Read More

View Article and Full-Text PDF

Anakinra Activates Superoxide Dismutase 2 to Mitigate Inflammasome Activity.

Int J Mol Sci 2021 Jun 18;22(12). Epub 2021 Jun 18.

Department of Medicine and Surgery, University of Perugia, 06132 Perugia, Italy.

Inflammasomes are powerful cytosolic sensors of environmental stressors and are critical for triggering interleukin-1 (IL-1)-mediated inflammatory responses. However, dysregulation of inflammasome activation may lead to pathological conditions, and the identification of negative regulators for therapeutic purposes is increasingly being recognized. Anakinra, the recombinant form of the IL-1 receptor antagonist, proved effective by preventing the binding of IL-1 to its receptor, IL-1R1, thus restoring autophagy and dampening NLR family pyrin domain containing 3 (NLRP3) activity. Read More

View Article and Full-Text PDF

Multisystem Inflammatory Syndrome in an Adult (MIS-A) Successfully Treated with Anakinra and Glucocorticoids.

Microorganisms 2021 Jun 28;9(7). Epub 2021 Jun 28.

Department of Infectious-Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, 37024 Negrar di Valpolicella, Italy.

During the current SARS-CoV-2 pandemic, a novel syndrome termed "multisystem inflammatory syndrome in children" (MIS-C) has emerged. MIS-C was linked to COVID-19 and shared some features with Kawasaki disease and Toxic Shock Syndrome, with a common pathogenetic substrate of hyperinflammation and cytokine storm. Lately, MIS was also described in adults (≥21 years of age) and named "MIS-A". Read More

View Article and Full-Text PDF

Description and Analysis of Cytokine Storm in Registered COVID-19 Clinical Trials: A Systematic Review.

Pathogens 2021 Jun 2;10(6). Epub 2021 Jun 2.

Infectious Disease Unit, Specialty Internal Medicine, Johns Hopkins Aramco Healthcare, Dhahran 31311, Saudi Arabia.

The purpose of this systematic review was to describe the characteristics of clinical trials that focused on COVID-19 patients with cytokine release syndrome (CRS) and the variability in CRS definitions. Two authors independently searched three clinical trial registries and included interventional clinical trials on COVID-19 hospitalized patients that required at least one elevated inflammatory biomarker. Relevant data, including the type and cutoff of the measured biomarker, oxygen/respiratory criteria, fever, radiologic criteria, and medications, were summarized. Read More

View Article and Full-Text PDF

Targeting interleukin-1 for reversing fat browning and muscle wasting in infantile nephropathic cystinosis.

J Cachexia Sarcopenia Muscle 2021 Jun 30. Epub 2021 Jun 30.

Division of Pediatric Nephrology, Department of Pediatrics, Rady Children's Hospital San Diego, University of California, San Diego, La Jolla, CA, USA.

Background: Ctns mice, a mouse model of infantile nephropathic cystinosis, exhibit hypermetabolism with adipose tissue browning and profound muscle wasting. Inflammatory cytokines such as interleukin (IL)-1 trigger inflammatory cascades and may be an important cause for cachexia. We employed genetic and pharmacological approaches to investigate the effects of IL-1 blockade in Ctns mice. Read More

View Article and Full-Text PDF

Paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): a narrative review and the viewpoint of the Latin American Society of Pediatric Intensive Care (SLACIP) Sepsis Committee.

BMJ Paediatr Open 2021 4;5(1):e000894. Epub 2021 Feb 4.

Pediatric Intensive Care Unit Ricardo Gutiérrez Children's Hospital, Sepsis Committee. Latin American Society of Pediatric Intensive Care (SLACIP), Buenos Aires, Argentina.

Background: In this review, we discuss some important aspects of paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS), a new syndrome that is temporally related to previous exposure to SARS-CoV-2 infection. This virus has a broad spectrum of presentation that may overlap with Kawasaki disease in terms of presenting symptoms and laboratory and cardiac findings. Our objective was to review and summarise published evidence regarding the most important aspects of PIMS-TS, with special emphasis on the treatment strategies suggested for middle-income and low-income countries. Read More

View Article and Full-Text PDF
February 2021

Recombinant Production and One-Step Purification of IL-1Ra in Escherichia coli and Evaluation of its IL-1 Antagonizing Efficacy.

Iran J Immunol 2021 Jun;18(2):126-130

Department of Pharmaceutical Biotechnology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.

Background: Anakinra (Kineret®), an IL-1 receptor antagonist, is the first FDA-approved biologic drug for antagonizing IL-1 in patients with Rheumatoid arthritis. The less expensive production of this drug might help reduce the final therapeutic costs.

Objectives: To evaluate the possibility of producing biologically active recombinant IL-1Ra by a single-step purification procedure mediated by a self-cleavable intein. Read More

View Article and Full-Text PDF

Seizure control after late introduction of anakinra in a patient with adult onset Rasmussen's encephalitis.

Epilepsy Behav Rep 2021 31;16:100462. Epub 2021 May 31.

ERGO - Epilepsy Research Group of Oslo, Department of Neurology, Oslo University Hospital, PO Box 4950 Nydalen, 0424 Oslo, Norway.

Neuroinflammation has been considered an important pathophysiological process involved in epileptogenesis and may provide possibilities for new treatment possibilities. We present the case of a 45-year-old female with drug resistant epilepsy and progressive right-sided cerebral hemiatrophy associated with adult onset Rasmussen's encephalitis. Over a period of 26 years, she was treated with 14 different antiseizure medications, intravenous immunoglobulins, glucocorticosteroids, underwent two operations with focal resection and subpial transections, and tried out trigeminal nerve stimulation. Read More

View Article and Full-Text PDF

Intravenous administration of anakinra in children with macrophage activation syndrome.

Pediatr Rheumatol Online J 2021 Jun 29;19(1):98. Epub 2021 Jun 29.

Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.

Background: Subcutaneous anakinra is an interleukin-1 inhibitor used to treat juvenile idiopathic arthritis. Recent reports suggest anakinra can be a valuable addition to the treatment of COVID-19 associated cytokine storm syndrome and the related multisystem inflammatory syndrome (MIS-C) in children. Herein, we describe our experience with intravenously administered anakinra. Read More

View Article and Full-Text PDF